Literature DB >> 24816189

Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity.

Valérie Lang1, Chiara Pallara2, Amaia Zabala3, Sofia Lobato-Gil4, Fernando Lopitz-Otsoa5, Rosa Farrás6, Roland Hjerpe7, Monica Torres-Ramos8, Lorea Zabaleta9, Christine Blattner10, Ronald T Hay11, Rosa Barrio12, Arkaitz Carracedo13, Juan Fernandez-Recio14, Manuel S Rodríguez15, Fabienne Aillet16.   

Abstract

The tumor suppressor p53 regulates the expression of genes involved in cell cycle progression, senescence and apoptosis. Here, we investigated the effect of single point mutations in the oligomerization domain (OD) on tetramerization, transcription, ubiquitylation and stability of p53. As predicted by docking and molecular dynamics simulations, p53 OD mutants show functional defects on transcription, Mdm2-dependent ubiquitylation and 26S proteasome-mediated degradation. However, mutants unable to form tetramers are well degraded by the 20S proteasome. Unexpectedly, despite the lower structural stability compared to WT p53, p53 OD mutants form heterotetramers with WT p53 when expressed transiently or stably in cells wild type or null for p53. In consequence, p53 OD mutants interfere with the capacity of WT p53 tetramers to be properly ubiquitylated and result in changes of p53-dependent protein expression patterns, including the pro-apoptotic proteins Bax and PUMA under basal and adriamycin-induced conditions. Importantly, the patient derived p53 OD mutant L330R (OD1) showed the more severe changes in p53-dependent gene expression. Thus, in addition to the well-known effects on p53 stability, ubiquitylation defects promote changes in p53-dependent gene expression with implications on some of its functions.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Oligomerization; Proteasome; Transcription; Ubiquitylation; p53

Mesh:

Substances:

Year:  2014        PMID: 24816189      PMCID: PMC5528522          DOI: 10.1016/j.molonc.2014.04.002

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  55 in total

1.  MoDEL (Molecular Dynamics Extended Library): a database of atomistic molecular dynamics trajectories.

Authors:  Tim Meyer; Marco D'Abramo; Adam Hospital; Manuel Rueda; Carles Ferrer-Costa; Alberto Pérez; Oliver Carrillo; Jordi Camps; Carles Fenollosa; Dmitry Repchevsky; Josep Lluis Gelpí; Modesto Orozco
Journal:  Structure       Date:  2010-11-10       Impact factor: 5.006

2.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

Review 3.  20S proteasomes and protein degradation "by default".

Authors:  Gad Asher; Nina Reuven; Yosef Shaul
Journal:  Bioessays       Date:  2006-08       Impact factor: 4.345

4.  In vivo ubiquitination and proteasome-mediated degradation of p53(1).

Authors:  C G Maki; J M Huibregtse; P M Howley
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

5.  Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation.

Authors:  C G Maki; P M Howley
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

6.  Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.

Authors:  P D Jeffrey; S Gorina; N P Pavletich
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

7.  Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway.

Authors:  D R Chowdary; J J Dermody; K K Jha; H L Ozer
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

8.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.

Authors:  W Maltzman; L Czyzyk
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

9.  Regulation of p53 activity through lysine methylation.

Authors:  Sergei Chuikov; Julia K Kurash; Jonathan R Wilson; Bing Xiao; Neil Justin; Gleb S Ivanov; Kristine McKinney; Paul Tempst; Carol Prives; Steven J Gamblin; Nickolai A Barlev; Danny Reinberg
Journal:  Nature       Date:  2004-11-03       Impact factor: 49.962

10.  Refined solution structure of the oligomerization domain of the tumour suppressor p53.

Authors:  G M Clore; J Ernst; R Clubb; J G Omichinski; W M Kennedy; K Sakaguchi; E Appella; A M Gronenborn
Journal:  Nat Struct Biol       Date:  1995-04
View more
  10 in total

1.  C-terminal region of human p53 attenuates buffalo p53 N-terminal-specific transactivation of p21 promoter by modulating tetramerization of the protein.

Authors:  Minu Singh; Tapas Mukhopadhyay
Journal:  Mol Cell Biochem       Date:  2017-11-16       Impact factor: 3.396

2.  Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.

Authors:  Ariadne H A G Ooms; Samantha Gadd; Daniela S Gerhard; Malcolm A Smith; Jaime M Guidry Auvil; Daoud Meerzaman; Qing-Rong Chen; Chih Hao Hsu; Chunhua Yan; Cu Nguyen; Ying Hu; Yussanne Ma; Zusheng Zong; Andrew J Mungall; Richard A Moore; Marco A Marra; Vicki Huff; Jeffrey S Dome; Yueh-Yun Chi; Jing Tian; James I Geller; Charles G Mullighan; Jing Ma; David A Wheeler; Oliver A Hampton; Amy L Walz; Marry M van den Heuvel-Eibrink; Ronald R de Krijger; Nicole Ross; Julie M Gastier-Foster; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

3.  Analysis of defective protein ubiquitylation associated to adriamycin resistant cells.

Authors:  Valérie Lang; Fabienne Aillet; Wendy Xolalpa; Sonia Serna; Laurie Ceccato; Rosa G Lopez-Reyes; Maria Paz Lopez-Mato; Radosław Januchowski; Niels-Christian Reichardt; Manuel S Rodriguez
Journal:  Cell Cycle       Date:  2017-11-20       Impact factor: 4.534

Review 4.  p53 and Its Isoforms in Renal Cell Carcinoma-Do They Matter?

Authors:  Agata Swiatkowska
Journal:  Biomedicines       Date:  2022-06-06

5.  p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.

Authors:  Nicholas W Fischer; Aaron Prodeus; David Malkin; Jean Gariépy
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

6.  LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation.

Authors:  Kaixuan Zeng; Xiaoxiang Chen; Xiuxiu Hu; Xiangxiang Liu; Tao Xu; Huiling Sun; Yuqin Pan; Bangshun He; Shukui Wang
Journal:  Oncogene       Date:  2018-06-13       Impact factor: 9.867

7.  Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity.

Authors:  Valérie Lang; Chiara Pallara; Amaia Zabala; Sofia Lobato-Gil; Fernando Lopitz-Otsoa; Rosa Farrás; Roland Hjerpe; Monica Torres-Ramos; Lorea Zabaleta; Christine Blattner; Ronald T Hay; Rosa Barrio; Arkaitz Carracedo; Juan Fernandez-Recio; Manuel S Rodríguez; Fabienne Aillet
Journal:  Mol Oncol       Date:  2014-04-13       Impact factor: 6.603

8.  Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.

Authors:  Romi Biswas; Shaojian Gao; Constance M Cultraro; Tapan K Maity; Abhilash Venugopalan; Zied Abdullaev; Alexey K Shaytan; Corey A Carter; Anish Thomas; Arun Rajan; Young Song; Stephanie Pitts; Kevin Chen; Sara Bass; Joseph Boland; Ken-Ichi Hanada; Jinqiu Chen; Paul S Meltzer; Anna R Panchenko; James C Yang; Svetlana Pack; Giuseppe Giaccone; David S Schrump; Javed Khan; Udayan Guha
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-11

9.  Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers.

Authors:  Ana Maria Low-Calle; Joshua H Choe; Chen Katz; Oleg Laptenko; David Tong; Jazmine-Saskya N Joseph-Chowdhury; Francesca Garofalo; Yan Zhu; Assaf Friedler; Carol Prives
Journal:  Genes Dev       Date:  2018-03-16       Impact factor: 11.361

Review 10.  p53 tetramerization: at the center of the dominant-negative effect of mutant p53.

Authors:  Jovanka Gencel-Augusto; Guillermina Lozano
Journal:  Genes Dev       Date:  2020-09-01       Impact factor: 11.361

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.